J&J to acquire Ollin Biosciences: Phase 1b data suggest greater retinal drying with OLN324 than faricimab in DME

Johnson & Johnson has agreed to acquire Ollin Biosciences and its lead candidate OLN324, an investigational VEGF/Ang2 bispecific antibody being developed for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). OLN324 is advancing into global Phase 3 clinical development.

J&J to acquire Ollin Biosciences: Phase 1b data suggest greater retinal drying with OLN324 than faricimab in DME

Johnson & Johnson announced, that it has entered into a definitive agreement to acquire Ollin Biosciences, a clinical-stage biopharmaceutical company based in Austin, Texas. With this agreement, Johnson & Johnson would add to its pipeline OLN324, an investigational bispecific antibody designed to target two key pathways involved in retinal diseases: vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2).

Molecule design

Building on the clinical development of intravitreal VEGF/Ang2 inhibition, OLN324 is a next-generation VEGF/Ang2 bispecific antibody. According to the company, it has up to 60-fold higher anti-Ang2 potency than faricimab, is designed to allow a higher molar dose than both faricimab and aflibercept (including Eylea HD®), and has a smaller protein format (minibody). 

VEGF and Ang2 are important drivers of retinal vascular diseases such as DME and wet AMD. Ang2 contributes to vascular instability, leakage, inflammation, and fibrosis. OLN324 was discovered by and is being developed in collaboration with Innovent Biologics.

The JADE study

JADE is a randomized, head-to-head Phase 1b clinical study comparing OLN324 with faricimab in 164 patients with DME or neovascular AMD at sites in the United States. All patients initially received three monthly intravitreal injections of either OLN324 2 mg, OLN324 4 mg, or faricimab 6 mg. Patients were evaluated at Weeks 1, 4, 8, 12, 16, and 20 and could be retreated at Weeks 12 or 16 based on protocol-specified retreatment criteria that were the same for all groups.

The primary objective was to assess safety and tolerability. Prespecified exploratory efficacy objectives included visual acuity and various retinal anatomical parameters, with efficacy outcomes evaluated at Week 12. Results with OLN324 2 mg were generally similar to those with the 4 mg dose.

Results in DME

OLN324 showed greater reductions in retinal thickness than faricimab in patients with DME. With OLN324 4 mg, the mean reduction in central subfield thickness (CST), measured by optical coherence tomography (OCT), was approximately 75% greater than with faricimab at Week 1 (–79 µm vs. –45 µm) and approximately 50% greater at Week 12 (–180 µm vs. –121 µm).

Nearly 90% of patients treated with OLN324 4 mg reached a CST below 325 µm at Week 12, compared with 57% of patients treated with faricimab. This threshold was used in the study as an operational definition of absence of DME. 

At the final study visit at Week 20, 12 weeks after the last mandatory dose, patients treated with OLN324 continued to show numerically greater reductions in CST than those treated with faricimab. Vision gains were also numerically greater with OLN324 4 mg. These outcomes were accompanied by a slightly lower retreatment rate: 93% of DME patients randomized to OLN324 4 mg completed the 12-week follow-up period without retreatment, compared with 89% in the faricimab group.

“DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases. The difference in speed and extent of retinal drying observed with OLN324 versus faricimab, the highest bar comparator in DME, is compelling and clinically significant,” said Arshad M. Khanani, M.D., Sierra Eye Associates, a JADE study investigator and member of Ollin’s Scientific Advisory Board.

Results in neovascular AMD

In neovascular AMD, all treatment groups showed comparable improvements in retinal thickness, as measured by mean OCT CST changes, beginning as early as Week 1. These improvements were sustained through Week 20.

Patients treated with OLN324 experienced numerically greater vision gains than those treated with faricimab. The differences in best-corrected visual acuity (BCVA) continued to increase numerically between Weeks 12 and 20, with a mean advantage of 2.2 letters for OLN324 4 mg at Week 20. No statistical significance was reported for this difference.

At Week 20, 82% of patients treated with OLN324 4 mg had completed the 12-week follow-up period without retreatment, compared with 81% of patients treated with faricimab.

In prespecified analyses, patients with neovascular AMD randomized to OLN324 4 mg showed a faster and approximately 50% greater reduction in pigment epithelial detachment (PED) thickness at Week 12 than patients treated with faricimab, measured as mean change in neovascular lesion complex thickness on OCT. According to Ollin, these improvements were more durable through Week 20, during the off-treatment follow-up period.

Ollin reports that PEDs are present in approximately 80% of patients with neovascular AMD. Persistent PEDs following anti-VEGF treatment have been associated with the development of subretinal fibrosis, an important contributor to late vision loss in wet AMD.

“These data suggest that OLN324’s more potent Ang2 inhibition and smaller molecular format may translate into breaking through the efficacy ceiling experienced with current treatments and offering a clinically-relevant benefit in PED improvement – the most difficult to treat component of wAMD,” said David Eichenbaum, M.D., Retina Vitreous Associates of Florida.

Safety

No cases of intraocular inflammation (IOI) were observed in patients treated with OLN324 during the study, compared with one case in a faricimab-treated patient. There were no reported cases of retinal vasculitis or occlusive retinal vasculitis in the OLN324 treatment groups.

These findings are encouraging, although the relatively small number of patients and the Phase 1b study design do not allow reliable assessment of the risk of rare adverse events.

Phase 3 development to include European sites

Subject to regulatory communications, Ollin expects the Phase 3 studies of OLN324 in DME and wet AMD to recruit patients from North America, South America, Europe, and Japan.

Three Phase 3 studies have been registered on ClinicalTrials.gov: GOBI (OLN324-CP-03, NCT07842016) in DME, which compares OLN324 with aflibercept as active comparator in an estimated 450 patients, and OLN324-CP-04 (NCT07816315) and OLN324-CP-05 (NCT07816289) in wet AMD.

Under a separate development funding agreement, Blackstone Life Sciences will provide Johnson & Johnson with $750 million over multiple years to fully fund the Phase 3 development of OLN324. In return, Blackstone will be eligible for certain regulatory and sales milestone payments, as well as single-digit royalties.

Deal terms

Johnson & Johnson will acquire Ollin for $2.2 billion upfront, with potential regulatory and commercial milestone payments of up to approximately $1.125 billion. The transaction is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions. Ollin was founded in 2023.

Sources: Johnson & Johnson and Ollin Biosciences press releases of November 16, 2026; Ollin Biosciences press releases of January 8 and March 30, 2026; ClinicalTrials.gov (NCT07842016, NCT07816315, NCT07816289).